Omnia SanaPlant Comparison
Pot marigold vs Common coltsfoot
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Pot marigold and Common coltsfoot: both belong to the Asteraceae family; they share 3 indicated uses (arthritis / joint pain, inflammation (general), skin irritation); 1 pharmacological action in common.
Evidence face-off — shared uses
| Condition | Pot marigold | Common coltsfoot | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 5/10 | 1/10 | Stronger for Pot marigold |
| Inflammation (general) | 5/10 | 2/10 | Stronger for Pot marigold |
| Skin irritation | 5/10 | 1/10 | Stronger for Pot marigold |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Principal wound-healing and anti-inflammatory constituents of the flower.
Antioxidant flavonoids and carotenoids give the flower its orange-yellow colour and contribute to its antioxidant activity.
Minor aromatic and resinous constituents of the flower head.
Hepatotoxic constituents that are the central safety concern for this plant; regulatory limits and PA-controlled/PA-reduced products exist specifically because of these compounds.
Demulcent polysaccharide contributing to the traditional soothing action on irritated airways.
Pharmacological Actions
Calendula officinalis extracts show cytotoxic antitumor, pro-apoptotic and antimetastatic activity across many cancer cell lines and in animal models (preclinical).
Traditional & Indicated Uses
inferred from anti-inflammatory action
A Calendula officinalis (LACE) aqueous extract inhibits proliferation (70-100%) of leukemia, melanoma, breast, prostate, lung and colon cancer cell lines via G0/G1 arrest and caspase-3 apoptosis and inhibits melanoma growth in nude mice; a systematic review documents its cytotoxic and antimetastatic antitumour activity (preclinical).
inferred from antifungal action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from sedative action
Safety, Cautions & Contraindications
Generally very safe for topical use. May cause contact dermatitis in rare cases (Asteraceae family allergy). Internal use is safe in normal doses. Avoid during pregnancy at therapeutic doses (uterine stimulant potential). Generally safe during breastfeeding for topical use.
Duke (2002) rates calendula (Calendula officinalis) and notes anti-inflammatory, wound-healing (vulnerary), antifungal, and antispasmodic activities at experimental levels. Commission E (KOM) approves calendula flower for wound healing and anti-inflammatory uses, both topically and as a gargle. The plant contains flavonoids, triterpene saponins (oleanolic acid glycosides), and essential oils. Dose: 1–2 g dried flower as tea (for mouth rinse/gargle); or as cream/ointment containing 2–5% calendula extract for topical use. Duke notes that calendula is generally very well-tolerated, though Asteraceae sensitivity can occasionally cause allergic reactions (Duke, 2002).
Safety notes (contraindications, interactions, pregnancy/lactation notes, adverse effects, dose-duration cautions) Important: Coltsfoot naturally contains pyrrolizidine alkaloids (PAs)—plant chemicals that can damage the liver and may increase cancer risk with enough exposure (EMA, 2021; Kopp et al., 2020).
Because of this, European regulators set very strict limits for PA exposure from herbal products (EMA, 2021).
Many safety-focused herbal references recommend avoiding homemade/internal coltsfoot use, unless the product is specifically made to be PA-controlled / PA-reduced (EMA, 2021).
Avoid internal use if you are pregnant or breastfeeding, have liver disease, or for children—these groups are treated as “sensitive” in PA risk guidance (EMA, 2021).
Medication caution: if you take medicines that stress the liver (some prescription drugs can), it’s extra important to avoid unregulated PA exposure (general PA risk logic; consult a clinician) (EMA, 2021).
Topical use may still carry PA considerations; EMA discusses limits and recommends use only on intact skin for PA-containing products (EMA, 2021).
Duke (2002) provides clinical support (score 2) for coltsfoot's anti-inflammatory and expectorant effects, explaining its traditional use in bronchitis and coughs. However, the plant contains hepatotoxic pyrrolizidine alkaloids (PAs), and Duke notes a carcinogenic score (1) — a critical safety concern. Commission E has placed restrictions on coltsfoot use, recommending maximum internal use of 4–6 weeks per year and avoiding use in pregnancy, lactation, and in children under 12. Duke rates its overall safety as low (+) and emphasizes that preparations free of PAs are preferred (Duke, 2002).
External Ids
Botanical Description
Aromatic annual or short-lived perennial herb with soft, hairy, oblong leaves and branching, slightly sticky stems. The flower heads are bright orange to yellow, daisy-like, with numerous narrow ray florets surrounding a darker central disc, opening in sunlight and closing at dusk.[1]
Low perennial herb notable for flowering before its leaves appear: solitary, bright yellow, dandelion-like flower heads emerge on scaly pinkish stalks in very early spring, followed later by large, hoof-shaped (heart-shaped with angular teeth), white-woolly-backed leaves arising directly from the creeping rhizome.[11]
Habitat
Widely cultivated as a garden and medicinal plant; believed native to southern Europe and the Mediterranean, now naturalised in gardens and waste ground worldwide.[1]
Grows on disturbed, damp or clay-rich waste ground, riverbanks, railway embankments and bare soil; native to Europe, North Africa and temperate Asia and naturalised in North America.[11]
Harvesting
The flower heads (or just the ray-floret petals) are picked by hand as they open, through the flowering season, and dried quickly in a warm, shaded, airy place to preserve colour and resin content.[1]
Flowers are gathered in very early spring before the leaves appear; leaves are gathered later in the season once expanded. Given the plant's pyrrolizidine alkaloid content, harvesting from a positively confirmed patch (not a look-alike) and preferring PA-tested commercial material for internal use is strongly advised.[2]
Traditional Uses
Calendula flower is one of the most widely used topical wound-healing and skin-soothing herbs in Western herbal medicine, applied to cuts, grazes, minor burns and skin inflammation, and used internally as a gentle anti-inflammatory and antimicrobial remedy and as a gargle for mouth and throat irritation.[1]
Coltsfoot has an ancient European and Chinese tradition, reflected in its Latin name (tussis = cough), as an expectorant and demulcent remedy for coughs, bronchitis and irritated airways; because of its pyrrolizidine alkaloid content, contemporary use is restricted to short courses of PA-controlled preparations under regulatory limits (see contraindications).[1, 2, 12]
Preparations
Dried petals infused in a carrier oil, used as a soothing base for topical creams and balms for skin healing.
Standardised flower extract formulated into a cream or ointment for topical wound and skin care; the best-studied modern form.
Dried flower infused in hot water, 1-2 g in 150 ml, used still warm as a mouth rinse or gargle 2-4 times daily. The EU herbal monograph's posology for this preparation is OROMUCOSAL only - it does not support taking the infusion internally. Educational reference only, not a prescription.
Commercially prepared, pyrrolizidine-alkaloid-tested extract or syrup, the only form recommended for internal use given the plant's natural PA content.
Dried flower or leaf infused in hot water; traditional but subject to strict duration/PA-content limits under EU herbal regulation.
Dosage
The EU herbal monograph gives semi-solid preparations containing the equivalent of 2-10% herbal substance, applied as a thin layer to the affected area 2 to 4 times daily. Educational reference only, not a prescription.
The EU herbal monograph gives 1-2 g of the flower in 150 mL water as an infusion, used still warm for rinsing and gargling 2 to 4 times daily, or to prepare impregnated dressings for the skin. This is an oromucosal and cutaneous preparation, not an oral tea. Educational reference only, not a prescription.
EU regulatory guidance restricts internal use to PA-controlled preparations. The EMA public statement on unsaturated pyrrolizidine alkaloids records a maximum daily intake for internal use of 1 microgram of PAs for at most 6 weeks per year, or 0.1 microgram per day with no duration limit; for cutaneous use the limits are 100 micrograms for at most 6 weeks per year, or 10 micrograms without a duration limit. Not for use in pregnancy, breastfeeding, or children. Note that these are limits on PA intake, not a herb dose — no EMA monograph exists for Tussilago farfara, so there is no official posology for the herb itself. Educational reference only, not a prescription — consult a qualified practitioner and prefer tested commercial products.
References
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Givol, O., Kornhaber, R., Visentin, D., Cleary, M. et al (2019) 'A systematic review of Calendula officinalis extract for wound healing', Wound Repair and Regeneration, 27(5), pp. 548-561. doi:10.1111/wrr.12737 Meta-analysis / review
https://doi.org/10.1111/wrr.12737 - Shahane, K., Kshirsagar, M., Tambe, S., Jain, D. et al (2023) 'An Updated Review on the Multifaceted Therapeutic Potential of Calendula officinalis L', Pharmaceuticals (Basel), 16(4), pp. 611. doi:10.3390/ph16040611 Traditional / reference
https://doi.org/10.3390/ph16040611 - Saffari, E., Mohammad-Alizadeh-Charandabi, S., Adibpour, M., Mirghafourvand, M. et al (2016) 'Comparing the effects of Calendula officinalis and clotrimazole on vaginal Candidiasis: A randomized controlled trial', Women & Health, 57(10), pp. 1145-1160. doi:10.1080/03630242.2016.1263272 Randomized trial
https://doi.org/10.1080/03630242.2016.1263272 - Cruceriu, D., Balacescu, O. and Rakosy, E (2018) 'Calendula officinalis: potential roles in cancer treatment and palliative care', Integrative Cancer Therapies, 17(4), pp. 1068-1078. doi:10.1177/1534735418803766 Meta-analysis / review
https://doi.org/10.1177/1534735418803766 - Rezai, S., Rahzani, K., Hekmatpou, D. and Rostami, A (2023) 'Effect of oral Calendula officinalis on second-degree burn wound healing', Scars, Burns & Healing, 9, pp. 20595131221134053. doi:10.1177/20595131221134053 Randomized trial
https://doi.org/10.1177/20595131221134053 - Kadowaki, W., Miyata, R., Mizuno, S., Fujinami, M., Sato, Y. and Kumazawa, S (2023) 'Prenylated acetophenones from the roots of Calendula officinalis and their anti-inflammatory activity', Bioscience, Biotechnology, and Biochemistry, 87(7), pp. 683-687. doi:10.1093/bbb/zbad042 Preclinical
https://doi.org/10.1093/bbb/zbad042 - Samra, R.M., Maatooq, G.T. and Zaki, A.A (2022) 'A new antiprotozoal compound from Calendula officinalis', Natural Product Research, 36(22), pp. 5747-5752. doi:10.1080/14786419.2021.2023868 Preclinical
https://doi.org/10.1080/14786419.2021.2023868 - Kaur, J., Sidhu, S., Chopra, K. and Khan, M.U (2016) 'Calendula officinalis ameliorates l-arginine-induced acute necrotizing pancreatitis in rats', Pharmaceutical Biology, 54(12), pp. 2951-2959. doi:10.1080/13880209.2016.1195848 Preclinical
https://doi.org/10.1080/13880209.2016.1195848 - Aro, A.A., Perez, M.O., Vieira, C.P., Esquisatto, M.A.M., Rodrigues, R.A.F., Gomes, L. and Pimentel, E.R (2014) 'Effect of Calendula officinalis cream on achilles tendon healing', Anatomical Record, 298(2), pp. 428-435. doi:10.1002/ar.23057 Preclinical
https://doi.org/10.1002/ar.23057 - Zhang, X., Wang, R., Finiuk, N., Stoika, R., Lin, H., Wang, X. and Jin, M (2023) 'Active compounds from Calendula officinalis flowers act via PI3K and ERK signaling pathways to offer neuroprotective effects against Parkinson's disease', Food Science & Nutrition, 12(1), pp. 450-458. doi:10.1002/fsn3.3792 Preclinical
https://doi.org/10.1002/fsn3.3792 - Kadowaki, W., Miyata, R., Fujinami, M., Sato, Y. and Kumazawa, S (2023) 'Catechol-O-methyltransferase inhibitors from Calendula officinalis leaf', Molecules, 28(3), pp. 1333. doi:10.3390/molecules28031333 Preclinical
https://doi.org/10.3390/molecules28031333 - European Medicines Agency (HMPC) (2018) 'European Union herbal monograph on Calendula officinalis L., flos, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-calendula-officinalis-l-flos-revision-1_en.pdf - Hoffmann, D (2003) 'Medical Herbalism'. Traditional / reference
https://scholar.google.com/scholar?q=Medical%20Herbalism - Nicolaus, C. et al (2017) 'A double-blind, randomized controlled trial to investigate the efficacy and safety of a monograph-based Calendula cream versus a comparator cream', 35(1), pp. 81--89. Randomized trial
https://scholar.google.com/scholar?q=A%20double-blind%2C%20randomized%20controlled%20trial%20to%20investigate%20the%20efficacy%20and%20safety%20of%20a%20monograph-based%20Calendula%20cream%20versus%20a%20comparator%20cream - Preethi, K.C. and Kuttan, R (2009) 'Wound healing activity of flower extract of Calendula officinalis', 20(1), pp. 73--79. doi:10.1515/jbcpp.2009.20.1.73 Preclinical
https://doi.org/10.1515/jbcpp.2009.20.1.73 - Jimenez-Medina, E. and Garcia-Lora, A. and Paco, L. and Algarra, I. and Collado, A. and Garrido, F (2006) 'A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation', BMC Cancer, 6, pp. 119. doi:10.1186/1471-2407-6-119 Preclinical
https://doi.org/10.1186/1471-2407-6-119 - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
- Ahmad, I., Kudaibergenova, B., Ahmad, M. and others (2025) 'Coltsfoot (Tussilago farfara L.; Asteraceae): modern methods of extraction, phytochemistry, nanoparticles synthesis, ethnopharmacology, and biological activities', Natural Product Research, pp. 1-20. doi:10.1080/14786419.2025.2548616 Traditional / reference
https://doi.org/10.1080/14786419.2025.2548616 - Chen, S., Dong, L., Quan, H., Zhou, X. and others (2020) 'A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)', Journal of Ethnopharmacology, 267, pp. 113478. doi:10.1016/j.jep.2020.113478 Traditional / reference
https://doi.org/10.1016/j.jep.2020.113478 - Feng, J., Zhang, Y., Qin, X., Gao, T. and others (2022) 'Novel Quinic Acid Glycerates from Tussilago farfara Inhibit Polypeptide GalNAc-Transferase', ChemBioChem, 23(3), pp. e202100539. doi:10.1002/cbic.202100539 Preclinical
https://doi.org/10.1002/cbic.202100539 - Zhao, J., Evangelopoulos, D., Bhakta, S., Gray, A.I. and Seidel, V (2014) 'Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents', Journal of Ethnopharmacology, 155(1), pp. 796-800. doi:10.1016/j.jep.2014.06.034 Preclinical
https://doi.org/10.1016/j.jep.2014.06.034 - Avila, C., Breakspear, I., Hawrelak, J., Salmond, S. and Evans, S (2020) 'A systematic review and quality assessment of case reports of adverse events for borage (Borago officinalis), coltsfoot (Tussilago farfara) and comfrey (Symphytum officinale)', Fitoterapia, 142, pp. 104519. doi:10.1016/j.fitote.2020.104519 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2020.104519 - Lee, J., Park, S., Kim, M.J., Kwon, S.J. and others (2019) 'Sesquiterpenoids from Tussilago farfara Flower Bud Extract for the Eco-Friendly Synthesis of Silver and Gold Nanoparticles Possessing Antibacterial and Anticancer Activities', Nanomaterials (Basel), 9(6), pp. 819. doi:10.3390/nano9060819 Preclinical
https://doi.org/10.3390/nano9060819 - Bota, V.B., Neamtu, A.A., Olah, N.K., Chiselita, O. and others (2022) 'A Comparative Analysis of the Anatomy, Phenolic Profile, and Antioxidant Capacity of Tussilago farfara L. Vegetative Organs', Plants (Basel), 11(13), pp. 1663. doi:10.3390/plants11131663 Preclinical
https://doi.org/10.3390/plants11131663 - Boucher, M.A., Cote, H., Pichette, A., Ripoll, L. and Legault, J (2020) 'Chemical composition and antibacterial activity of Tussilago farfara (L.) essential oil from Quebec, Canada', Natural Product Research, 34(4), pp. 545-548. doi:10.1080/14786419.2018.1489384 Preclinical
https://doi.org/10.1080/14786419.2018.1489384 - Li, Z.Y., Zhang, J., Zhang, Y.B., Yang, X.W. and others (2022) 'Polyhydroxylated eudesmane sesquiterpenoids and sesquiterpenoid glucoside from the flower buds of Tussilago farfara', Chinese Journal of Natural Medicines, 20(4), pp. 301-308. doi:10.1016/S1875-5364(21)60120-6 Preclinical
https://doi.org/10.1016/S1875-5364(21)60120-6 - Jang, H., Lee, J.W., Lee, C., Jin, Q. and others (2016) 'Sesquiterpenoids from Tussilago farfara inhibit LPS-induced nitric oxide production in macrophage RAW 264.7 cells', Archives of Pharmacal Research, 39(1), pp. 127-132. doi:10.1007/s12272-015-0667-7 Preclinical
https://doi.org/10.1007/s12272-015-0667-7 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Westendorf, J., Czok, G., Marquardt, R., Nausner, M., Krauer, B. and Paul, H.L (1988) 'Pyrrolizidine alkaloid content of Tussilago farfara plants from different regions and preparations', pp. 903--909. Traditional / reference
https://scholar.google.com/scholar?q=Pyrrolizidine%20alkaloid%20content%20of%20Tussilago%20farfara%20plants%20from%20different%20regions%20and%20preparations - European Medicines Agency (HMPC) (2021) 'Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs), including recommendations regarding contamination of herbal medicinal products with PAs, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Sperl, W. and Stuppner, H. and Gassner, I. and Judmaier, W. and Dietze, O. and Vogel, W (1995) 'Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea', European Journal of Pediatrics, 154(2), pp. 112-6. doi:10.1007/BF01991912 Clinical study
https://doi.org/10.1007/BF01991912
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.